+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Hormonal Contraceptive Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • PDF Icon

    Report

  • 140 Pages
  • November 2023
  • Region: Global
  • IMARC Group
  • ID: 5912259

Quick Summary:

In the landscape of global healthcare, the utility and advancement of hormonal contraceptives stand as a testament to innovation and public health necessity. These pharmaceuticals serve a pivotal role in reproductive health management, offering individuals reliable options for family planning and various therapeutic benefits. The market for these products has shown resilience and growth, signaling the sustained demand and the critical importance of such healthcare solutions.

As a strategic tool for executives and industry stakeholders, this comprehensive market research report delves into the multifaceted developments propelling the hormonal contraceptive sector. An increasing global awareness surrounding reproductive rights, coupled with the thoughtful implementation of health initiatives, underscores the market's expansion. Innovations leading to reduced side effects and enhanced preventive measures are catering to a broader demographic, further stimulating market vigor. The report meticulously segments the industry by product, hormone, age group, and end user while providing a compelling competitive analysis, setting the foundation for informed decision-making and strategic planning.

The global hormonal contraceptive market size reached US$ 17.9 Billion in 2022. Looking forward, the market is expected to reach US$ 22.9 Billion by 2028, exhibiting a growth rate (CAGR) of 4.19% during 2022-2028.

Hormonal contraceptives are formulations of progestin or a combination of estrogen and progesterone hormones. They act on the endocrine system to prevent ovulation and fertilization. As a result, they are used for preventing unwanted pregnancies and are also known to relieve period pain and often result in lighter periods. Hormonal contraceptives are considered one of the most effective methods, which can be taken before and after vaginal intercourse. They include birth control pills, vaginal rings, contraceptive skin patches, and hormone-releasing contraceptive coils. Hormonal contraceptives also affect the womb lining, making it hard for the fertilized eggs to be implanted.

Hormonal Contraceptive Market Trends

The global hormonal contraceptive market is primarily driven by the increasing awareness among the masses regarding family planning. This has facilitated the need to prevent unintended pregnancies, especially among young couples. Furthermore, a significant rise in health issues associated with teenage pregnancies is promoting the use of contraceptives as they are easily accessible. Governments of different countries are also adopting various initiatives to support and improve access to these products by promoting affordable and high-quality healthcare services. Besides this, the advancements in the healthcare industry have resulted in the production of innovative products such as hormonal patches, implants, intrauterine devices, and drug-device combination products. These devices have fewer side effects and enhanced levels of efficiency in preventing pregnancy, which is favorably influencing the growth of the market.

Key Market Segmentation

This research provides an analysis of the key trends in each sub-segment of the global hormonal contraceptive market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on product, hormone, age group and end user.

Breakup by Product:

  • Oral Contraceptive Pills
  • Intrauterine Device (IUD)
  • Injectable Birth Control
  • Vaginal Rings

Breakup by Hormone:

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

Breakup by Age Group:

  • 15-24 Years
  • 25-34 Years
  • 35-44 Years
  • Above 44 Years

Breakup by End User:

  • Hospitals and Clinics
  • Homecare
  • Ambulatory Surgical Centers

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Latin America
  • Brazil
  • Mexico
  • Middle East and Africa

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players being Afaxys Inc., Agile Therapeutics Inc., Allergan Inc. (AbbVie Inc.), Bayer AG, Cipla Limited, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Piramal Group and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global hormonal contraceptive market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hormonal contraceptive market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the hormone?
  • What is the breakup of the market based on the age group?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hormonal contraceptive market and who are the key players?
  • What is the degree of competition in the industry?
Frequently Asked Questions about the Global Hormonal Contraceptive Market

What is the estimated value of the Global Hormonal Contraceptive Market?

The Global Hormonal Contraceptive Market was estimated to be valued at $17.9 Billion in 2022.

What is the growth rate of the Global Hormonal Contraceptive Market?

The growth rate of the Global Hormonal Contraceptive Market is 4.2%, with an estimated value of $22.9 Billion by 2028.

What is the forecasted size of the Global Hormonal Contraceptive Market?

The Global Hormonal Contraceptive Market is estimated to be worth $22.9 Billion by 2028.

Who are the key companies in the Global Hormonal Contraceptive Market?

Key companies in the Global Hormonal Contraceptive Market include Fulgent Genetics, Gene By Gene Ltd. (MyDNA), Illumina Inc., Invitae Corporation, MedGenome Labs Ltd., Myriad Genetics Inc., Natera Inc., OPKO Health Inc., Quest Diagnostics and Sema4.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hormonal Contraceptive Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Oral Contraceptive Pills
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Intrauterine Device (IUD)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Injectable Birth Control
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Vaginal Rings
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Hormone
7.1 Progestin-only Contraceptive
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Combined Hormonal Contraceptive
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Age Group
8.1 15-24 Years
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 25-34 Years
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 35-44 Years
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Above 44 Years
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals and Clinics
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Homecare
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Ambulatory Surgical Centers
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Afaxys Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.2 Agile Therapeutics Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.3 Allergan Inc. (AbbVie Inc.)
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.4 Bayer AG
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Cipla Limited
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Johnson & Johnson
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Merck & Co. Inc.
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Pfizer Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Piramal Group
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.10 Teva Pharmaceutical Industries Ltd
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis

Companies Mentioned

  • Afaxys Inc.
  • Agile Therapeutics Inc.
  • Allergan Inc. (AbbVie Inc.)
  • Bayer AG
  • Cipla Limited
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Piramal Group
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...